- GlobeNewswire•2 days agoSanthera Starts Phase III Study (SIDEROS) with Raxone in Patients with Duchenne Muscular Dystrophy Using Glucocorticoids
Liestal, Switzerland, September 28, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces that the first patient has been enrolled at the University of Kansas Medical Center (KUMC), Department of Neurology, ...
- GlobeNewswire•17 days agoLeading medical journal publishes treatment effect of Santhera's Raxone on inspiratory function in patients with Duchenne muscular dystrophy (DMD)
Liestal, Switzerland, September 13, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces that additional data from the pivotal phase III trial (DELOS) demonstrating efficacy of Raxone (idebenone) on inspiratory ...
- GlobeNewswire•22 days agoSanthera's Idebenone (Raxone) Receives Orphan Drug Designation for Duchenne Muscular Dystrophy in Australia
Liestal, Switzerland, September 8, 2016 - Santhera Pharmaceuticals (SWX: SANN), announces today that the Australian Therapeutic Goods Administration (TGA) has granted orphan drug designation (ODD) to idebenone ...
SANTHERA N (SANN.SW)
Swiss - Swiss Delayed Price. Currency in CHF
|Day's Range||52.10 - 53.40|
|52wk Range||48.50 - 121.40|
|1y Target Est||N/A|
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||28,983|
|Dividend & Yield||N/A (N/A)|